ZYNLONTA®
Indolent Non-Hodgkin Lymphomas
Key Facts
About ADC Therapeutics
ADC Therapeutics is a commercial-stage oncology company with a mission to transform cancer treatment through its proprietary ADC platform. Its key achievement is the FDA approval and commercialization of ZYNLONTA® for relapsed/refractory large B-cell lymphoma, establishing a revenue base. The company's strategy is to maximize ZYNLONTA's potential through label expansion while leveraging its differentiated linker/payload technology to advance a focused pipeline in high-need oncology indications.
View full company profile